Rheb Inhibitors
Common Rheb Inhibitors include, but are not limited to Farnesyl thiosalicylic acid CAS 162520-00-5, Rapamycin CAS 53123-88-9, 6-Azauridine CAS 54-25-1, AS 1842856 CAS 836620-48-5 and Rocaglamide CAS 84573-16-0.
Rheb inhibitors belong to a specific chemical class of compounds meticulously designed to modulate the activity of the Rheb protein. Rheb, also known as Ras homolog enriched in brain, is a crucial component of intracellular signaling pathways that regulate cell growth, nutrient sensing, and protein synthesis. These inhibitors are thoughtfully crafted molecules engineered to interact with the Rheb protein, influencing its normal function. Through these interactions, they might impact various cellular processes associated with cellular growth, nutrient utilization, and signaling cascades, without directly altering its involvement in molecular complexes or its role in downstream signaling events.
The design of Rheb inhibitors is grounded in a comprehensive understanding of the structural and functional attributes of the Rheb protein. Typically developed using advanced chemical synthesis methods and informed by insights from molecular biology, these inhibitors are characterized by their ability to selectively bind to Rheb. This selectivity enables focused modulation of cellular pathways that rely on the activity of this specific protein. Unraveling the intricacies of cell growth regulation, nutrient sensing, and signaling networks often employ Rheb inhibitors as valuable tools. The development and utilization of Rheb inhibitors contribute to advancing our knowledge of the complex interplay between cellular components and intracellular signaling dynamics, offering insights into the fundamental molecular mechanisms that govern cellular growth and contribute to cellular responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Farnesyl thiosalicylic acid | 162520-00-5 | sc-205322 sc-205322A | 1 mg 5 mg | $61.00 $82.00 | 15 | |
Farnesyl thiosalicylic acid is an experimental Rheb inhibitor. It may disrupt Rheb's post-translational modification, farnesylation, leading to altered mTOR signaling and downstream effects on cell growth and proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, while primarily known as an mTOR inhibitor, indirectly affects Rheb. It binds to the mTORC1 complex, preventing its activation by Rheb, ultimately inhibiting mTORC1-mediated cell growth and protein synthesis. | ||||||
6-Azauridine | 54-25-1 | sc-221082B sc-221082 sc-221082C sc-221082A | 500 mg 1 g 2 g 5 g | $97.00 $159.00 $295.00 $679.00 | ||
6-Azauridine is a nucleoside analog that may inhibit Rheb by disrupting its function. The exact mechanism is not well-established, but it may impact Rheb-related signaling pathways involved in cell growth and metabolism. | ||||||
AS 1842856 | 836620-48-5 | sc-507096 sc-507096A | 10 mg 50 mg | $99.00 $415.00 | ||
AS 1842856 is another compound that may inhibit Rheb. Its mechanism of action is not fully elucidated, but it could impact Rheb-related pathways, potentially affecting mTORC1 signaling and downstream processes. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $275.00 $474.00 $1639.00 $2497.00 $5344.00 | 4 | |
Rocaglamide compounds have been suggested as Rheb inhibitors. They may influence mTORC1 signaling by targeting Rheb, thereby affecting cellular responses related to growth and protein synthesis. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin may impact Rheb-mediated pathways, contributing to its potential role in metabolic and anti-cancer effects. | ||||||